SUBSCRIBE
SUBSCRIBE
News   Policy

Amgen’s (JOBS) Bone Drug May Face Delays In FDA Decision

October 16, 2009 | 
1 min read
Bookmark and Share

NEW YORK (Dow Jones)--Biotech investors had circled Oct. 19 as the day that Amgen Inc.'s (AMGN) osteoporosis drug denosumab gets approved, but they may have to wait longer.
Regulatory
Amgen Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Health saving account, HSA, financial plan saving for medical expense or medicare cost and benefits concept, doctor with stethoscope standing with huge pink piggy bank or coin bank with medical sign.
Drug pricing
In Affordability Push, EMD Serono Joins TrumpRx While Roche Launches DTC Program
October 17, 2025
 · 
2 min read
 · 
Tristan Manalac
Human resource management and recruitment concept. Job rotation or staff turnover icon.
Government
FDA’s Orphan Drug Director Out Amid IRA Exemption Rollout
October 16, 2025
 · 
2 min read
 · 
Tristan Manalac
Washington, D.C., USA- January 13, 2020: FDA Sign at its headquarters in Washington DC. The Food and Drug Administration (FDA or USFDA) is a federal agency of the USA.
Gene therapy
FDA’s Second Platform Designation Goes to Krystal After Sarepta Withdrawal
October 15, 2025
 · 
2 min read
 · 
Tristan Manalac
Podcast
Q3 Earnings Are Here, Novo Ditches Cell Therapy but Buys Akero, Gov’t Shutdown Hits CDC
October 15, 2025
 · 
1 min read
 · 
Heather McKenzie